Kurser indlæses...
Prognose
Vi har ingen analytikerdata for denne virksomhed.
Diskussioner i communityet
Der er endnu ingen diskussion om dette aktiv.
Start diskussionNyheder Til nyhedsfeedet
Abivax reports loss per share of $1.71 in quarter ended June 30, 2026
Abivax released results for the quarter ended June 30, 2026, reporting a loss per share of $1.71. In the same quarter a year earlier, the loss was $0.86 per share. The stock fell by around 4.5%. » Mere på finanzen.net
Abivax to release quarterly results for period ended 30 June 2026 on 21 September 2026
Abivax will publish its balance sheet for the quarter ended 30 June 2026 on 21 September 2026. Six analysts expect on average a loss per share of -0.917 USD (prior year -0.860 USD). Seven analysts forecast revenue of around 0.8 million USD versus 0.0 million USD in the year-ago quarter. For the current fiscal year analysts see on average a loss per share of -3.762 USD (prior year -5.450 USD) and annual revenue of 4.4 million USD on average. » Mere på finanzen.net
Abivax publishes quarterly results for 30.06.2026, analysts see another loss
Abivax will present the quarterly results for the period ending 30.06.2026 on 21.09.2026. Six analysts expect a quarterly loss per share of -0.801 EUR (previous year: -0.760 EUR) and seven analysts estimate revenue of 0.7 million EUR (previous year: 0.0 million EUR). For the fiscal year, 14 analysts on average forecast a loss per share of -3.291 EUR (previous year: -4.830 EUR) with average revenue of 3.8 million EUR (previous year: 0.0 million EUR). » Mere på finanzen.net
Abivax expects Q2 EPS of -0.839 EUR and revenue of about 0.7 million EUR
Abivax is expected to publish its quarterly figures for 30/06/2026 on 21/09/2026. Analysts on average forecast earnings of -0.839 EUR per share for the quarter (previous year: -0.760 EUR) and revenue of around 0.7 million EUR (previous year: 0.0 million EUR). For the current fiscal year, the average analyst outlook is a loss of -3.309 EUR per share and revenue of about 3.8 million EUR. » Mere på finanzen.net
Abivax expects quarterly results on September 21, 2026 with another EPS loss
For the quarter for which Abivax will report figures on September 21, 2026, five analysts forecast an average earnings per share of -0.959 USD, a decline of 11.51% from -0.860 USD a year earlier. Six analysts expect revenue of on average 0.8 million USD versus 0.0 million in the year‑ago quarter. For the fiscal year, 13 analysts on average forecast a loss per share of -3.778 USD (prior year -5.450 USD) and 14 analysts see revenue at an average of 4.4 million USD. » Mere på finanzen.net
Virksomhedstal
| (EUR) | december 2025 | YoY |
|---|---|---|
| Omsætning | -2,02 mio. | - |
| Bruttofortjeneste | -3,09 mio. | - |
| Nettoresultat | -235,32 mio. | - |
| EBITDA | -155,96 mio. | - |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 6,93 mia. € |
Antal aktier | 87,55 mio. |
Højeste/laveste i 52 uger | 139,00 € - 60,70 € |
| Udbytte | Nej |
Beta | -0,21 |
P/E (PE Ratio) | -16,79 |
PEG (PEG Ratio) | 0,30 |
K/I (PB Ratio) | 17,20 |
P/S (PS Ratio) | -3.433,08 |
Virksomhedsprofil
ABIVAX Société Anonyme opdager og optimerer lægemidler til behandling af inflammatoriske sygdomme, infektionssygdomme og kræft i Frankrig. Virksomhedens vigtigste produkter omfatter ABX464, som er i fase IIb-kliniske forsøg til behandling af colitis ulcerosa og Crohns sygdom samt til COVID-19; fase IIa-klinisk forsøg til behandling af reumatoid artrit; og har gennemført et fase IIa-klinisk forsøg til behandling af virologisk remission hos patienter med hiv. Virksomheden udvikler desuden ABX 196, en kandidat til immunforstærkning, som er i fase 1/2-kliniske forsøg til behandling af hepatocellulært carcinom. Derudover driver virksomheden forskningsprogrammer til behandling af denguefeber, influenza og respiratorisk syncytialvirus. ABIVAX Société Anonyme har licenskontrakter med det franske nationale center for videnskabelig forskning, Université de Montpellier og Institut Curie. Virksomheden blev stiftet i 2013 og har hovedkontor i Paris, Frankrig.
| Navn | Abivax |
| CEO | Marc de Garidel |
| Hjemsted | Paris,
if Frankrig |
| Websted | |
| Børsnotering | 26.06.2015 |
| Medarbejdere | 69 |
Tickersymboler
| Børs | Symbol |
|---|---|
London Stock Exchange | 0RA9.L |
Euronext | ABVX.PA |
Pnk | AAVXF |
Frankfurt | 2X1.F |
Düsseldorf | 2X1.DU |
London | 0RA9.L |
Paris | ABVX.PA |
München | 2X1.MU |